| Title |
Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it
|
|---|---|
| Published in |
Supportive Care in Cancer, September 2014
|
| DOI | 10.1007/s00520-014-2430-x |
| Pubmed ID | |
| Authors |
Sumiyo Ito, Ikuto Tsukiyama, Masahiko Ando, Masayo Katakami, Rie Hamanaka, Kenshi Kosaka, Ayako Matsubara, Masaki Nishimura, Hiroyuki Tanaka, Nobuhiro Asai, Norihito Yokoe, Ayumu Takahashi, Kenji Baba, Katsuhiko Matsuura, Etsuro Yamaguchi, Akihito Kubo |
| Abstract |
Neurokinin-1 (NK-1) receptor antagonist is recommended for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) and has recently been introduced to oncology practice in Japan. However, whether all patients undergoing HEC truly need NK-1 receptor antagonist remains unknown, and increasing medical costs due to uniform use of NK-1 receptor antagonist are a concern. This study was conducted to examine the prevalence of patients who needed aprepitant at the time of its introduction in Japan, and therapeutic and preventive effects of aprepitant on HEC or moderately emetogenic chemotherapy (MEC). |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 40% |
| Student > Master | 2 | 20% |
| Student > Bachelor | 2 | 20% |
| Student > Ph. D. Student | 1 | 10% |
| Unknown | 1 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 30% |
| Nursing and Health Professions | 2 | 20% |
| Psychology | 2 | 20% |
| Agricultural and Biological Sciences | 1 | 10% |
| Economics, Econometrics and Finance | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 1 | 10% |